NCT03480750View on ClinicalTrials.gov

Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

October 31, 2015

Study Completion Date

December 31, 2019

Conditions
Ovarian Neoplasms Malignant (Excl Germ Cell)Peritoneal CarcinomaFallopian Tube Cancer
Interventions
DRUG

trientine dihydrochloride

trientine dihydrochloride 300MG/CAPSUE PO daily (in different dose levels)

DRUG

pegylated liposomal doxorubicin

pegylated liposomal doxorubicin 40mg/m2 IV D1

DRUG

carboplatin

carboplatin AUC 4 IV D1

All Listed Sponsors
lead

National Cheng-Kung University Hospital

OTHER

NCT03480750 - Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter